Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2016

David Freedman's Biography



David Freedman, Co-Founder & CEO, nanoView Diagnostics Inc.

David Freedman Image

LATE-BREAKING PRESENTATION: A Platform For Characterization of Single Exosomes

Friday, 30 September 2016 at 07:30

Add to Calendar ▼2016-09-30 07:30:002016-09-30 08:30:00Europe/LondonLATE-BREAKING PRESENTATION: A Platform For Characterization of Single ExosomesLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Nanoview Diagnostics has developed a label-free visible-light microarray imaging technique that allows enumeration and sizing of individual nanovesicles captured on the sensor. The NVDX technology enables multiplexed (10-100’s) phenotyping of exosomes in a one-step assay direct-from-sample and can work with samples volumes as small as 5 µl. The NVDX exosome visualization technology is a direct-from-sample high-throughput technique than can improve standardization of exosome preparations and facilitate translation of exosome based liquid biopsies.


Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com